Cardiovascular disease and prevention among people living with HIV in South Florida

Fahim Pyarali, MD, MPH, Roumen Iordanov, MD, Bertrand Ebner, MD, Jelani Grant, MD, Louis Vincent, MD, Alexander Toirac, MD, Tahir Haque, MD, Gerardo Zablah, MD, Kunal Kapoor, MD, MSc, Alexis Powell, MD, Catherine Boulanger, MD, Barry Hurwitz, PhD, Maria Alcaide, MD, Claudia Martinez, MD

Abstract
Antiretroviral therapy (ART) has improved survival of patients living with HIV (PLWH); however, this has been accompanied by an increase in cardiovascular disease (CVD). Although preventative measures for CVD among the general population are well described, information is limited about CVD prevention among PLWH. The goal of this study was to characterize the prevalence of CVD in our population and to assess the use of primary and secondary prevention.

We performed a retrospective review of PLWH receiving primary care at a large academic center in Miami, Florida. We characterized the prevalence of CVD, CVD risk, and the use of aspirin and statins for primary and secondary CVD prevention.

A total of 985 charts were reviewed (45% women, 55% men). Average age was 52.2 years. Average CD4 count was 568 cells/μL. 92.9% were receiving ART, and 71% were virologically suppressed. The median 10-year ASCVD risk was 7.3%. The prevalence of CVD was 10.4% (N = 102). The odds of having CVD was lower in patients on ART (OR 0.47, 95% CI: 0.25–0.90, P = .02). The use of medications for primary and secondary prevention of CVD based on current guidelines was low: 15% and 37% for aspirin respectively, and 25% and 44% for statins.

CVD risk and rates of CVD are high among PLWH and receiving ART could protect against CVD. However, the use of medications for primary and secondary prevention is low. Increased awareness of CVD risk-reduction strategies is needed among providers of PLWH to decrease the burden of CVD.

Abbreviations: ART = antiretroviral therapy, ASCVD = atherosclerotic cardiovascular disease, CD4 = CD4+ T helper cells, CI = confidence interval, CVD = cardiovascular disease, HbA1c = hemoglobin A1C, HIV = human immunodeficiency virus, IQR = interquartile range, IRB = Institutional Review Board, LDL-C = low-density lipoprotein cholesterol, OR = odds ratio, PLWH = patients living with HIV, SD = standard deviation.

Keywords: cardiovascular disease, epidemiology, HIV, primary prevention, secondary prevention

1. Introduction
The advent and improved accessibility to anti-retroviral therapy (ART) for the treatment of HIV has afforded patients living with HIV (PLWH) an increased life expectancy.[1,11] Subsequently, these patients are now manifesting the burden of chronic, non-communicable diseases, such as cardiovascular disease (CVD).[12–14] CVD is the leading cause of death in PLWH, with a nearly 2-fold increased incidence of cardiovascular events compared with uninfected counterparts.[5,6] It has been previously shown that PLWH have higher rates of CVD compared with HIV-uninfected controls in all age groups.[7]

Multiple factors have been thought to contribute to the development of CVD among PLWH.[8–10] These include a high prevalence of traditional CVD risk factors, such as smoking, hypertension, obesity, and diabetes mellitus, the presence of chronic inflammation and immune activation associated with aging and HIV, as well as the cardiometabolic dysfunction associated with the use of some ARTs.[12,11–15] In combination, these factors lead to a prothrombotic state, the presence of vascular dysfunction, and the subsequent development of frank CVD.[16–22]

Statin medications, used to decrease lipid abnormalities, possess anti-inflammatory properties that may limit vascular and myocardial inflammation, subsequently reducing atherogenesis.[23,24] There are strong data supporting statin use for both
primary and secondary prevention of cardiovascular disease among the general population. Based on current guidelines, the role of statin therapy in primary prevention is determined by the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score. However, conventional stratification models such as ASCVD and Framingham risk scores have been shown to underestimate risk in PLWH and do not take into account nonclinical risk factors, such as subclinical inflammation and noncalcified plaques, which often affect PLWH. Yet, current models that incorporate inflammatory markers and ART regimens do not improve model performance and lack external validity. As a result, the American College of Cardiology 2018 guidelines for the management of blood cholesterol aim to bridge this risk estimation gap by including HIV as “risk enhancing factors” to re-stratify higher risk groups that may benefit from the use of statins. Still, information is limited regarding the use of these medications for CVD prevention among PLWH.

The state of Florida ranks among states with the highest overall prevalence of HIV in the United States, with Miami-Dade County in particular having the highest annual rate of newly diagnosed cases in 2017, per the Center for Disease Control and Prevention’s 2018 report. Further, Jackson Memorial Hospital administers the greatest number of HIV diagnostic assays in Miami, FL, and most of the PLWH in Miami are older than 50 years of age. The Center for Disease Control estimates that nearly 90% of this population with newly diagnosed HIV is composed of Hispanic and non-Hispanic black individuals. This study aims to identify the prevalence of CVD, CVD risk, and the use of aspirin and statins for primary and secondary CVD prevention among PLWH who receive HIV care at a large academic center in Miami, Florida.

2. Methods

This study was reviewed and approved by the Institutional Review Board at the University of Miami (IRB Number 20161109). This was a retrospective chart review of patients seen between 2017 and 2019 at the Jackson Memorial Hospital Special Immunology Clinic, located on the University of Miami/ Jackson Memorial Hospital medical campus. This clinic serves as the HIV subspecialty care clinic and provides primary care for PLWH. The majority of the patients are from under-represented minorities, older than 50 years of age, have low income, and receive HIV care through the Ryan White Program. No patients under the age of 18 were included in this study. The electronic medical record was used as the source of information. This entailed reviewing clinic notes, anthropometric data, laboratory tests, and diagnostic tests.

Physician notes were reviewed to identify the diagnoses of previous cardiovascular disease, relevant comorbidities (such as diabetes, chronic kidney disease, etc.), prescription of CVD and HIV-related medications, and lifestyle behaviors such as smoking or drug use. Anthropometric data were reviewed for blood pressure and body mass index. Review of laboratory tests included HIV-related markers such as CD4 counts and viral loads, and markers for cardiovascular risk such as cholesterol panels and hemoglobin A1C. We reviewed diagnostic testing for cardiovascular diseases that were on file, including echocardiograms and cardiac catheterization.

CVD was defined as the presence of any of the following: coronary artery disease, myocardial infarction, angina, peripheral arterial disease, cerebrovascular disease, congestive heart failure, or atrial fibrillation/atrial flutter. We considered essential hypertension, defined as the use of antihypertensives, as a risk factor for the development of CVD, but did not include it in our CVD prevalence estimates.

All data reviewed from the electronic medical record were de-identified and populated in a secure, encrypted online database using the RedCap electronic data capture tool. Statistical analyses were performed on reports generated from RedCap using Stata. Individuals with a diagnosed history of CVD were identified and prevalence was estimated for this population. ASCVD scores were calculated for all patients ages 40 to 79 for whom the necessary data was available (systolic blood pressure, lipid panel, smoking history, etc.). The prescription of antiplatelet and cholesterol-lowering medications for primary prevention in patients without known CVD was evaluated. This analysis was based on the latest guidelines from the United States Preventative Service Task Force. Among patients ages 50 to 70 with an ASCVD greater than 10%, we analyzed the number of individuals who were prescribed aspirin for primary prevention. In addition, we analyzed the number of individuals who were prescribed a statin for primary prevention among patients ages 40 to 75 with an ASCVD greater than 7.5%. We also analyzed the proportion of diabetic patients on a statin, as well as the proportion of patients with hyperlipidemia on a statin. We analyzed the uptake of antiplatelet and cholesterol-lowering medications for secondary prevention in patients with a diagnosed history of CVD.

To identify statistically significant differences in demographic and laboratory variables between PLWH with CVD and those without CVD, we used either t tests or Mann–Whitney U tests. For differences in categorical variables, we used Pearson Chi-Squared tests. P values less than .05 were considered significant. Univariate linear models were used to evaluate the relationship between ASCVD scores and HIV-related factors such as CD4 count and viral load. Multivariate logistic models with documented CVD as the binary outcome were used to identify possible predictors of CVD. We added variables in a step-wise fashion based on clinical judgement and known and hypothesized relationships between HIV and CVD.

3. Results

A total of 985 charts of PLWH were reviewed. Patients’ median age was 53 years old (Fig. 1), with a large percentage of women and a demographically diverse population (Table 1). The total prevalence of cardiovascular disease in this cohort was 10.4% (n=102), 11.0% prevalence in males, and 9.6% in females. A total of 141 cardiovascular events were identified, with the subtypes of CVD described in Table 2. Some patients had more than one cardiovascular event, hence the difference between prevalence and total events. In patients 40 to 79 years of age, the median 10-year ASCVD score for our population was 7.3% (IQR 2.9–14.4), and the average ASCVD score was 10.7% (SD 10.9). The distribution was heavily skewed to the left as shown in Figure 2.

We compared clinically relevant characteristics between seropositive individuals with a history of CVD (n=102) to those without a history of CVD (n=883). PLWH with CVD were significantly older than PLWH without CVD (59.8 vs 51.3 years, P=.001), with similar gender composition between groups.
PLWH with CVD had a lower proportion of Hispanic ethnicity but higher proportion of African American race \( (P = .003) \). Diagnosis of hypertension \( (P < .001) \), chronic kidney disease \( (P < .001) \), diabetes \( (P < .001) \), and hyperlipidemia \( (P = .004) \) were all significantly more frequent in patients with CVD. There was no difference in history of tobacco use, median blood pressures, and body-mass indices; however, PLWH with CVD had a lower median low-density lipoprotein cholesterol (LDL-C) and higher median HbA1c.

Aspirin was prescribed in 11% of the entire cohort \( (n = 107/985) \). The use of aspirin for primary prevention in patients ages 50 to 70 with an ASCVD risk score ≥ 10% was 15% \( (n = 40/262) \). The use of aspirin for secondary prevention in patients was 37% \( (n = 38/102) \). Statins were prescribed in 26% of the entire cohort \( (n = 253/985) \). The use of statins for primary prevention in patients ages 40 to 75 with an ASCVD risk score ≥ 7.5% was 25% \( (n = 70/276) \). The use of statins for secondary prevention in patients was 44% \( (n = 45/102) \). Statins were prescribed for 58% of diabetic patients \( (n = 97/166) \) (Supplemental Table 3, http://links.lww.com/MD/G247).

On review of HIV-related factors, the average CD4 count was 568.1 ± 337 cells/mm\(^3\), with median viral load of <200 IU/mL (IQR 0–31). Notably, 71.2% of cohort patients had an undetectable viral load (<200 IU/mL), and 92.9% of patients were on ART. However, PLWH with CVD had significantly lower proportion of ART treatment (87.3% vs 93.5%, \( P = .019 \)) despite no statistically significant difference in viral load or most recent CD4 count.

We used logistic regression with history of cardiovascular disease as the outcome to identify predictors of CVD. In a univariate model, being on ART was found to be protective against CVD \( (OR 0.47, 95% CI [0.25–0.90], P = .022, Table 2) \). This effect remained statistically significant after controlling for age, sex, diabetes, and smoking history \( (OR 0.37, 95% CI [0.19–0.74], P = .005, Supplemental Table 2, http://links.lww.com/MD/G247) \). An undetectable viral load was associated with 23.7% lower odds of having CVD, but this was not statistically significant \( (OR 0.763, 95% CI [0.49–1.18], P = .23, Table 2) \).

In multivariate logistic models (Supplemental Table 2, http://links.lww.com/MD/G247), age remained a consistently significant predictor in all models, with a 7.0% higher odds of having

![Figure 1. Age distribution of cohort.](Image of the histogram displaying the age distribution of patients that were analyzed as part of the study \( n = 985 \).)

### Table 1

| Characteristics of PLWH with and without history of CVD. |
|-----------------------------------------------------------|
| **Overall \( n = 985 \) | **History of CVD \( n = 102 \) | **Without CVD \( n = 883 \) | **P value** |
|---|---|---|---|
| **Sociodemographic factors** | | | |
| Average age (years) | 52.2 (SD 11.7) (range 22–88) | 59.8 | 51.3 | <.001 |
| Gender | 45% Female (447) 55% Male (538) | 42% Female (43) 58% Male (59) | 46% Female (40) 54% Male (477) | .490 |
| Race/ethnicity | 62% Black or AA (614) | 72% Black or AA (73) 21% | 61% Black or AA (541) 35% | .003 |
| White (37) 1% Others (5) | White (7) 1% Others (1) | White (30) 1% Others (4) | | |
| **CVD factors** | | | | |
| Smoking history | Yes: 24% (235) No: 76% (750) | Yes: 25% (25) No: 75% (77) | Yes: 24% (210) No: 76% (673) | .871 |
| Diagnosis of hypertension | Yes: 43% (428) No: 57% (557) | Yes: 75% (76) No: 25% (26) | Yes: 40% (352) No: 60% (531) | <.001 |
| Diagnosis of chronic kidney disease | Yes: 11% (111) No: 89% (874) | Yes: 28% (29) No: 72% (73) | Yes: 9% (82) No: 91% (801) | <.001 |
| Diagnosis of diabetes | Yes: 17% (166) No: 83% (819) | Yes: 30% (31) No: 70% (71) | Yes: 15% (135) No: 85% (748) | <.001 |
| Diagnosis of obesity | Yes: 35% (341) No: 65% (625) | Yes: 35% (36) No: 65% (66) | Yes: 35% (305) No: 65% (559) | .999 |
| Diagnosis of Hyperlipidemia | Yes: 43% (378) No: 57% (499) | Yes: 57% (52) No: 43% (49) | Yes: 41% (326) No: 59% (463) | .004 |
| Median BMI (kg/m\(^2\)) | 27.9 (IQR 23.9–32.1) | 27.3 (IQR 23.9–32.7) | 28.0 (IQR 24.0–32.1) | .804 |
| Median A1C (%) | 5.6 (IQR 5.3–6.0) | 5.8 (IQR 5.4–7.1) | 5.6 (IQR 5.3–5.9) | .003 |
| **HIV factors** | | | | |
| Median CD4 Count (cells/mm\(^3\)) | 531 (IQR 326–794) | 482 (IQR 272–738) | 536 (IQR 331–799) | .148 |
| Median viral load (copies/mL) | 0 (IQR 0–31, x̄ = 6263) | 0 (IQR 0–58, x̄ = 15,081) | 0 (IQR 0–29, x̄ = 7490) | .216 |
| Receiving ART | Yes: 93% (915) No: 7% (70) | Yes: 87% (89) No: 13% (13) | Yes: 94% (826) No: 6% (57) | .019 |
| Undetectable viral load | Yes: 71% (682) No: 29% (276) | Yes: 66% (60) No: 34% (34) | Yes: 72% (616) No: 28% (242) | .226 |

Table displaying the characteristics of the patients who were part of the chart review, categorized by sociodemographics, known cardiovascular disease factors, and HIV factors. The table also compares the characteristics of patients with documented CVD to those without documented CVD, with either \( t \) test or Mann–Whitney \( U \) test. For differences in categorical variables, Pearson Chi-Squared test was used. A1C = glycated hemoglobin, AA = African American, ART = antiretroviral therapy, BMI = body mass index, CVD = cardiovascular disease, HVN = human immunodeficiency virus, IQR = interquartile range, PLWH = people living with HIV, SD = standard deviation, \( x̄ \) = mean.
Prevalence and CVD diagnosis among PLWH; and odds of CVD by HIV factors.

| Number of patients | n   | %       |
|--------------------|-----|---------|
| Total prevalence of CVD | 102 | 985    | 10.4%  |
| Prevalence of CVD in Males | 59  | 538    | 11.0%  |
| Prevalence of CVD in Females | 43  | 447    | 9.6%   |

| Number of events | n   | %       |
|------------------|-----|---------|
| Total CVD events | 141 |         |        |
| Coronary artery disease | 17  | 985    | 1.7%   |
| Myocardial infarctions | 19  | 985    | 1.9%   |
| Angina           | 16  | 985    | 1.6%   |
| Peripheral vascular disease | 23  | 985    | 2.3%   |
| Cerebrovascular disease | 24  | 985    | 2.4%   |
| Congestive heart failure | 27  | 985    | 2.7%   |
| Atrial fibrillation/flutter | 15  | 985    | 1.5%   |

Odds ratio 95% CI P value

| Odds of CVD by undetectable status (log regression) | 0.76  | 0.49–1.18 | .23 |
| Odds of CVD by ART status (log regression)       | 0.47  | 0.25–0.90 | .022 |

Table displaying the number of cardiovascular disease events identified among patients with HIV, categorized by type of event. The table also reports the odds of cardiovascular disease by undetectable HIV status as well as the odds of cardiovascular disease by treatment with antiretroviral therapy. ART = antiretroviral therapy, CVD = cardiovascular disease, HIV = human immunodeficiency virus, PLWH = people living with HIV.

CVD for every year of life (OR 1.07, P < .001), even after controlling for viral suppression and other demographic and lifestyle variables. Gender was not a significant predictor in our models. However, being diabetic was associated with an approximately 1.7-fold higher odds of having CVD (OR 1.74, P = .03). CD4 count was shown to have a minimal protective effect against CVD after controlling for demographic and lifestyle variables, with a 0.1% lower odds for each CD4 cell, but it was not statistically significant (OR 0.999, P = .107, Supplemental Table 2, http://links.lww.com/MD/G247).

In evaluating predictors of ASCVD risk, neither CD4 count (P = .57) nor viral loads (P = .28) were significantly correlated with ASCVD 10-year estimated risk score in eligible patients (Supplemental Table 1, http://links.lww.com/MD/G247). Univariate linear models with ASCVD score as a continuous variable did not reveal a significant association with CD4 counts or viral loads (Supplemental Table 1, http://links.lww.com/MD/G247). Median ASCVD scores did not significantly differ between undetectable viral load (7.4% for undetectable vs 6.7% for detectable, P = .39) or ART status (9.7% on ART vs 7.2% not on ART, P = .10, Supplemental Table 1, http://links.lww.com/MD/G247).

4. Discussion

This study was the first to characterize the prevalence of CVD, CVD risk, and the use of aspirin and statins for primary and secondary CVD prevention among PLWH who receive HIV care in South Florida.

Results highlight that the overall prevalence of CVD amongst PLWH is high. These results are consistent with the AGE-IV Cohort Study in Amsterdam, which found a CVD prevalence of 10% among seropositive patients. However, the prevalence of myocardial infarction (1.9%) and cerebrovascular disease (2.4%) was found to be higher than previous reports (0.42% and 0.6% respectively) among PLWH. This is of concern as, PLWH with a history of myocardial infarction, cardiomyopathy, heart failure, or arrhythmia, have been shown to have a 4.5-fold increased risk for sudden cardiac death. Only 2.3% of our cohort carried a diagnosis of peripheral arterial disease, which is lower than other cohort studies, which report a peripheral artery disease prevalence between 4.4% and 12.3% among PLWH. These variations may reflect the demographic variations in the types of CVD manifestations in PLWH.

These results add to the growing body of evidence that demonstrates the increased burden of CVD in a population of PLWH that is aging. Studies suggest that PLWH with 1 CVD risk factor had a hazard ratio of 2.0 for myocardial infarctions, and those with 3 or more factors had a hazard ratio of 3.6 compared with seronegative controls. In our cohort, we found that patients with CVD were older, with a higher median hemoglobin A1C level and were less likely to be on ART. While median LDL-C levels were lower in the CVD group, this is likely due to the higher use of lipid-lowering medications in the CVD group. It should be noted that our cohort did not include seronegative controls, and we were thus unable to compare the relative associations of traditional risk factors and CVD between seropositive and seronegative individuals. In addition, our patient population had a larger proportion of individuals self-identifying as Black or African American and Hispanic compared with other published studies, which may make direct comparisons with other cohorts more difficult. However, the results of our study underscore the importance of addressing CVD risk factors in this demographic group. Although gender was not a significant predictor of CVD in our cohort, other studies have shown...
that HIV-positive females have a significantly higher risk of CVD compared with seronegative females.[47–49]

Some studies have demonstrated associations between ARTs and increased CVD risk.[14] In particular, protease inhibitors have been associated with dyslipidemia as well as increased fibrinogen levels.[20–22] Non-nucleoside reverse transcriptase inhibitors have also demonstrated an increase in total cholesterol and LDL-C in patients.[21] However, the START Trial showed that HIV-positive individuals on ART have a more favorable risk profile against CVD compared with those not on ART.[50] Our study showed that patients on ART therapy had a 63% reduction in the odds of having documented cardiovascular events, even when controlling for age, sex, diabetes, and smoking history (OR 0.37, 95% CI [0.19–0.74], P = .005, Supplemental Table 2, http://links.lww.com/MD/G247). This supports current knowledge that the HIV virus itself may contribute to an inflammatory cascade that promotes atherosclerosis irrespective of conventional CVD risk factors.[51,52] However, it is important to note in our study that while an undetectable viral load was associated with a lower odds of having documented CVD, this was not statistically significant in the univariate or multivariate models (OR 0.763, 95% CI [0.49–1.18], P = .23, Table 2). Our measurements of CD4 counts and viral loads were taken from the most recent clinic visit, and peak viral loads and CD4 troughs were not measured in this analysis. We cannot conclude from this study that the mechanism of the protective effect that ART has against CVD is through viral suppression. However, we can conclude that being on ART appears to overall be protective against CVD in PLWH.

Results of this study demonstrate a suboptimal utilization of antiplatelet and lipid-lowering agents for primary and secondary prevention of CVD among PLWH. A number of studies have reported underutilization of statin therapies for secondary prevention in the general population.[53–56] However, the phenomenon of underutilization of primary and secondary prevention is even more relevant for PLWH due to the enhanced CVD risk related to HIV.[37,57–62] Further, these results support existing data that report use of aspirin for primary prevention is lower among ethnic minorities patients in the US.[63]

While a few small studies on the use of statins have shown reduction of subclinical inflammation and improved mortality in HIV,[64,65] a large randomized placebo-controlled trial (REPRIEVE) is underway and has completed enrollment to evaluate the impact of pitavastatin on reducing coronary atherosclerosis in PLWH on ART at low-moderate traditional risk for CVD.[66,67] One of the caveats of current strategies to reduce CVD risk in PLWH is that ASCVD scores have been shown to under-predict low-to-moderate coronary artery disease risk in these patients.[25,29,30] This paradoxical underestimation of risk was noted in our patient cohort, in which the calculated median 10-year risk of CVD of the entire cohort was lower than the actual prevalence of documented cardiovascular events (7.3% median ASCVD risk vs 10.4% CVD prevalence).

4.1. Limitations

The biggest limitation of the study is the cross-sectional design, which does not allow for temporal or trend analysis of risk factor profiles over time, the duration of exposure to specific ARTs, or duration of exposure to HIV. Additionally, there was no HIV-negative control group for comparison. The retrospective design of this study is susceptible to sampling bias, as we included only patients who were seen at a dedicated HIV clinic. Since the study was a retrospective chart review, our definition of CVD events was limited by what was documented in the medical record. There might have been additional cardiovascular events that were not documented. Additionally, documentation of lifestyle factors such as tobacco, alcohol, and drug use was determined by self-report during clinical encounters, which might have been biased. Finally, there might have been other confounding variables that we did not account for in the data collection and in the multivariate analysis. Although this retrospective study was conducted at a single center in Miami, FL, the analysis offers unique opportunities of studying often underrepresented patient populations (female, Black, Hispanic) that make up the large majority of new cases of HIV, according to the Center for Disease Control annual report.[14]

5. Conclusion

The advent of antiretroviral therapy has substantially improved survival in PLWH. However, CVD risk and rates of CVD are now high among PLWH who receive ART, especially with increasing age and HbA1c levels.[4] Yet, the use of medications for primary and secondary prevention is low. Therefore, interventions to increase awareness of CVD risk reduction strategies among provider of PLWH are needed to decrease the burden of CVD among this aging population. In addition, attitudes and beliefs regarding prevention of CVD should be explored for healthcare providers caring for PLWH, and strategies to overcome barriers to effective primary and secondary prevention, whether structural, cultural, or educational, should be explored to reduce CVD morbidity and mortality.

Acknowledgments

Fahim F. Pyarali, MD, MPH – data collection, statistical analysis, manuscript writing
Roumen Iordanov, MD – data collection, statistical analysis, manuscript writing
Bertrand Ebner, MD – literature search, manuscript writing
Jelani Grant, MD – literature search, manuscript writing
Louis Vincent, MD – literature search, manuscript writing
Alexander Toirac, MD – literature search, manuscript writing
Tahir Haque, MD – data collection, manuscript writing
Gerardo Zablaha, MD – data collection, manuscript writing
Kunal Kapoor, MD, MSc – literature search, manuscript writing
Alexis Powell, MD – HIV patient provider, manuscript writing
Barry Hurwitz, PhD – HIV patient provider, manuscript writing
Maria Alcaide, MD – HIV patient provider, manuscript writing
Claudia Martinez, MD – principal investigator, manuscript writing

Author contributions

Conceptualization: Fahim Pyarali, Roumen Iordanov, Gerardo Zablaha.
Data curation: Louis Vincent, Alexander Toirac, Tahir Haque, Gerardo Zablak, Kunal Kapoor.

Formal analysis: Fahim Pyarali, Roumen Iordanov.

Investigation: Catherine Boulanger.

Methodology: Alexiss Powell, Catherine Boulanger, Barry Hurwitz, Maria Alcaide.

Supervision: Claudia Martinez.

Validation: Claudia Martinez.

Writing – original draft: Roumen Iordanov, Jelani Grant, Louis Vincent, Alexander Toirac, Kunal Kapoor.

Writing – review & editing: Fahim Pyarali, Roumen Iordanov, Bertrand Ebner, Louis Vincent, Claudia Martinez.

References

[1] Palella FJJr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–60.

[2] Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2306–12.

[3] Palella FJJr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27–34.

[4] Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol 2016;117:214–20.

[5] Shah ASV, Stelzl D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation 2018;138:1100–82.

[6] Toribio M, Neilan TG, Zanni MV. Heart failure among people with HIV: evolving risks, mechanisms, and preventive considerations. Curr HIV/AIDS Rep 2019;16:371–80.

[7] Feinstein MJ, Stevenson AB, Ning H, et al. Adjudicated heart failure in HIV-infected and uninfected men and women. J Am Heart Assoc 2018;7:e009855.

[8] Hsue PY, Giri K, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004;109:316–9.

[9] Benjamin LA, Allain TJ, Mzganga R, et al. The role of human immunodeficiency virus-associated vasculopathy in the etiology of stroke. J Infect Dis 2017;216:545–53.

[10] Vachtel A, McCutcheon K, Tsbedze N, Zachariah D, Manga P. HIV and ischemic heart disease. J Am Coll Cardiol 2017;69:73–82.

[11] Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014;160:458–67.

[12] Feinstein AAMJ. Coronary Artery Disease in HIV. Latest In Cardiology 2018; Accepted at: https://www.acci.org/latest-in-cardiology/articles/2018/01/180857/coronary-artery-disease-in-hiv. Accessed October, 2018.

[13] Tintani B, Gavegnano C, Hsue P, Schinazi R, Marconi VC. Targeting inflammation to reduce atherosclerotic cardiovascular risk in people with HIV infection. J Am Heart Assoc 2020;9:e014873.

[14] Currier JS, Hsue PY. The role of inflammation in HIV-associated atherosclerosis—size may not fit all. J Infect Dis 2020;221:495–7.

[15] Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318–30.

[16] Elion RA, Akhfo KN, Zhang J, et al. Recent Abacavir use increases risk of Type 1 and Type 2 myocardial infarctions among adults with HIV. J Acquir Immune Defic Syndr 2018;78:62–72.

[17] Group DADS, Fris-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723–33.

[18] Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012;13:453–68.

[19] McGettrick PMC, Mallon PWG. HIV and cardiovascular disease: defining the unmeasured risk. Lancet HIV 2018;5:e267–9.

[20] Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2000;182:1056–74.

[21] Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008;22:707–15.

[22] Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012;18:1519–30.

[23] Tian J, Gu Xu, Sun Y, et al. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord 2012;12:70.

[24] Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014;58:588–95.

[25] Force USPST , Bbibbs-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016;316:1997–2007.

[26] Baigent C, Blackwell L, et al. Cholesterol Treatment Trials Clficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–81.

[27] Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation 2019;140:e98–124.

[28] Triant VA, Perez J, Regan S, et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation 2018;137:2203–14.

[29] Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS research network of integrated clinical systems. JAMA Cardiol 2017;2:155–62.

[30] Grundy SM, Stone NJ, Bailey AL, et al. 2018AHA/ACC/AACVPR/AAPA/ABC/ACPMP/ADA/AGS/APhA/ASP/H/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:e285–350.

[31] Prevention CiDaC. HIV Surveillance Report, 2018 2019; Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed April, 2020.

[32] Escudero DJ, Bennett B, Suarez S, Darrow WW, Mayer KH, Seage GR3rd. Progress and challenges in “Getting to Zero” new HIV infections in Miami, Florida. J Int Assoc Provid AIDS Care 2019;18:GR3rd.

[33] Progress and challenges in “Getting to Zero” new HIV infections in Miami, Florida. J Int Assoc Provid AIDS Care 2019;18:GR3rd.

[34] Control CiDaC. Florida - State Health Profile. 2017; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Accessed October, 2018.

[35] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.

[36] Staata Statistical Software: Release 16 [computer program]. College Station, TX: StataCorp LLC; 2019.

[37] van Zoonen RA, van der Valk M, Wit FW, et al. Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. Eur J Prev Cardiol 2017;24:1297–307.

[38] Lang S, Boccara F, Mary-Krause M, Cohen A. Epidemiology of coronary heart disease in HIV-infected versus uninfected individuals in developed countries. Arch Cardiovasc Dis 2015;108:206–15.

[39] Arentzen M, Jubit F, Evers S, et al. Cerebrovascular events in HIV-infected patients: an analysis of a cohort of 3203 HIV+ patients during the times of cART. Int J Neurosci 2015;125:601–11.

[40] Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death on antiretroviral therapy. Eur J Prev Cardiol 2017;24:1297–307.

[41] Control CiDaC. Florida - State Health Profile. 2017; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Accessed October, 2018.

[42] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.
[43] Barnes RP, Lacson JC, Bahrami H. HIV infection and risk of cardiovascular diseases beyond coronary artery disease. Curr Atheroscler Rep 2017;19:20.

[44] Paisible AL, Chang CC, So-Armah KA, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 2015;68:209–16.

[45] Oramasionwu CU, Hunter JM, Brown CM, et al. Cardiovascular disease in Blacks with HIV/AIDS in the United States: a systematic review of the literature. Open AIDS J 2012;6:29–35.

[46] Carnethon MR, Pu J, Howard G, et al. Cardiovascular Health in African Americans: a scientific statement from the American Heart Association. Circulation 2017;136:e393–423.

[47] Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. J Acquir Immune Defic Syndr 2011;57:245–53.

[48] Womack JA, Chang CC, So-Armah KA, et al. HIV infection and cardiovascular disease in women. J Am Heart Assoc 2014;3:e001035.

[49] Hatleberg CI, Ryom L, El-Sadr W, et al. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. J Int AIDS Soc 2018;21:e25083.

[50] Baker JV, Sharma S, Achhra AC, et al. Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am Heart Assoc 2017;6:5.

[51] Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol 2014;11:728–41.

[52] Nordell AD, McKenna M, Borges AH, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014;3:e000844.

[53] Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol 2015;201 (suppl 1):S1–7.

[54] Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk and statin use in the United States. Ann Fam Med 2014;12:215–23.

[55] Brown F, Singer A, Katz A, Konrad G. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Can Fam Physician 2017;63:e495–503.

[56] Laleman N, Henrard S, van den Akker M, et al. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. BMC Cardiovasc Disord 2018;18:209.

[57] Clement ME, Park LP, Navar AM, et al. Statin utilization and recommendations among HIV- and HCV-infected Veterans: a cohort study. Clin Infect Dis 2016;63:407–13.

[58] Reinsch N, Neuhaus K, Esser S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol 2012;19:267–74.

[59] Marbaniang IP, Kadam D, Suman R, et al. Cardiovascular risk in an HIV-infected population in India. Heart Asia 2017;9: e010893.

[60] Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol 2017;8:6–14.

[61] Suchindran S, Regan S, Meigs JB, Grinspoon SK, Triant VA. Aspirin use for primary and secondary prevention in human immunodeficiency virus (HIV)-infected and HIV-uninfected patients. Open Forum Infect Dis 2014;1:ofu076.

[62] Burkholder GA, Tamhane AR, Salinas JL, et al. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis 2012;55:1550–7.

[63] Fernandez-Jimenez R, Wang TJ, Fuster V, Blot WJ. Low-dose aspirin for primary prevention of cardiovascular disease: use patterns and impact across race and ethnicity in the southern community cohort study. J Am Heart Assoc 2019;8:e013404.

[64] Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013;56:1471–9.

[65] Eckard AR, Cho S, O’Riordan MA, McComsey GA. Kallistatin levels in HIV-infected patients and effects of statin therapy. Biomarkers 2017;22:53–62.

[66] Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top Antivir Med 2015;23:16–74.

[67] Hoffmann U, Lu MT, Olalere D, et al. Rationale and design of the mechanistic substudy of the randomized trial to prevent vascular events in HIV (REPRIEVE): effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J 2019;212:1–12.